NeuroSense CEO to be Panelist at Cantor Neurology and Psychi

Company's lead drug candidate PrimeC is currently being evaluated in a Phase IIb trial, with topline data expected in mid-2023CAMBRIDGE, Mass., Se...

Related Keywords

Phoenix , Arizona , United States , University Of Arizona , Cambridge , Cambridgeshire , United Kingdom , San Francisco , California , American , Jeremy Shefner , Cantor Fitzgerald , Gregoryw Fulton , Charles Duncan , Clinical Trials Consortium , Linkedin , Department Of Neurology , Twitter , Barrow Neurological Institute , Drug Administration , Cantor Healthcare Team , Nasdaq , Neurosense Therapeutics Ltd , Neuromuscular Disease Center , European Medicines Agency , Neurosense Therapeutics , Cantor Neurology , Psychiatry Conference , New Treatment Paradigm , Scientific Advisory Board , Keynote Speaker , Disease Center , Executive Chair , American Board , Trials Consortium , Editorial Boards , Managing Director , Orphan Drug Designation , Sense Therapeutics , Neurosense Therapeutic ,